Analysts Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Target Price at $28.14

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $28.1429.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price on the stock. Oppenheimer started coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research lifted their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Finally, Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, CFO Vaseem Mahboob sold 26,287 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $25.88, for a total transaction of $680,307.56. Following the completion of the sale, the chief financial officer directly owned 60,609 shares in the company, valued at approximately $1,568,560.92. This trade represents a 30.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the transaction, the insider directly owned 475,215 shares in the company, valued at approximately $11,652,271.80. This trade represents a 9.85% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 223,164 shares of company stock valued at $5,288,752 in the last ninety days. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC acquired a new position in Kestra Medical Technologies in the 4th quarter valued at approximately $31,000. Russell Investments Group Ltd. lifted its position in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after buying an additional 474 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at $72,000. BNP Paribas Financial Markets grew its holdings in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after acquiring an additional 1,638 shares in the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares in the last quarter.

Kestra Medical Technologies Trading Up 1.0%

NASDAQ:KMTS opened at $28.02 on Thursday. The stock has a fifty day simple moving average of $23.81 and a 200 day simple moving average of $22.72. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -11.58 and a beta of 0.58. Kestra Medical Technologies has a 1-year low of $15.42 and a 1-year high of $30.00. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The company had revenue of $28.64 million for the quarter. Sell-side analysts forecast that Kestra Medical Technologies will post -2.29 earnings per share for the current year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.